ClinicalTrials.gg
Not yet recruitingNCT07331792Updated Jan 12, 2026

Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor

A Phase 1/2 interventional study of Topical 1 % clotrimazole twice daily 2 weeks and Oral itraconazole 200mg daily for 5 days in Pityriasis Versicolor, sponsored by Combined Military Hospital Abbottabad. Not yet recruiting. Open to participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Combined Military Hospital Abbottabad · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
15 Years to 50 Years
Sex
All
01

Study summary

Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial

02

Conditions studied

  • Pityriasis Versicolor
03

In context

Lead sponsor

Combined Military Hospital Abbottabad is the lead sponsor of 25 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (15-50 years)
  • Both genders
  • Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)

Exclusion criteria

Exclusion Criteria:

  • Pt with history of antifungals in last one month
  • Pt on or therapy
  • Pregnant and lactating women
  • Pt with chronic medical conditions ( Diabetes and hypertension)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    1% Clotrimazole

    topical 1 % clotrimazole twice daily for 2 weeks

    Drug: Topical 1 % clotrimazole twice daily 2 weeks

  • Experimental
    Itraconazole

    Oral itraconazole 200mg daily 5 days

    Drug: Oral itraconazole 200mg daily for 5 days

Interventions

06

What researchers measure

Primary outcomes

  1. Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor

    Data analysis will be performed using SPSS version 20. The quantitative variable (age, BMI and duration of PV) will be presented as mean ± standard deviation (SD) or median interquartile range (IQR) after checking normality of data by using Shapiro-Wilk test. Frequency and percentages will be used for categorical variables (gender, severity of PV, area of residence, level of education and efficacy). Efficacy will be compared between groups using Chi-square or Fisher exact test. Efficacy will be stratified by age, gender, BMI, duration of PV and severity of PV to deal with effect modifiers. Post-stratification chi-square test or Fischer exact test will be used as test of significance. A p-value of ≤ 0.05 will be considered statistically significant.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bamford JTM, Flores-GenuinoRNS, Ray S, Bigby M, Morales-Sánchez MA, Arkoncel M, et al. Interventions for the treatment of pityriasis versicolor. Cochrane Database Syst Rev. 2018;2018(6):CD011208. https://doi.org/10.1002/14651858.CD011208.pub2
  • Hill RC, Faria W, Gold JAW, Lipner SR. Factors associated with pityriasis versicolor in a large national database. Mycoses. 2024 Aug;67(8):e13775. doi: 10.1111/myc.13775. PubMed 39079943 ↗
  • Kurniadi I, Hendra Wijaya W, Timotius KH. Malassezia virulence factors and their role in dermatological disorders. Acta Dermatovenerol Alp Pannonica Adriat. 2022 Jun;31(2):65-70. PubMed 35751534 ↗
  • Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Drugs Context. 2022 Nov 14;11:2022-9-2. doi: 10.7573/dic.2022-9-2. eCollection 2022. PubMed 36452877 ↗
  • Labedz N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management. Life (Basel). 2023 Oct 22;13(10):2097. doi: 10.3390/life13102097. PubMed 37895478 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for May 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 12, 2026
StartEst.
Feb 2, 2026
Primary completionEst.
May 2, 2026
CompletionEst.
May 31, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07331792
Lead sponsor
Combined Military Hospital Abbottabad
Responsible party
Zaeema Aman (Resisent Dermatology, Combined Military Hospital Abbottabad) — Principal investigator
First posted
Jan 12, 2026
Start date
Feb 2, 2026 (estimated)
Primary completion
May 2, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Zaeema Aman, MBBS
Contact
zaeema.aman@gmail.com
+923200400726
Ali Amar, MBBS, FCPS
Contact
docaliamar@gmail.com
+923215625426

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion